Shanghai 捍宇医疗 (Hanyu Medical) develops minimally invasive interventional devices for mitral valve disease. Its core product, ValveClamp, is self‑developed, holds a global invention patent and is described as simple to operate, low‑trauma, with a large capture range and broad indications. ValveClamp completed a 12‑patient exploratory human clinical trial in October 2018 and initiated a pre‑market clinical trial in February 2019, becoming the first domestically developed mitral‑valve device to reach pre‑market trials in China. The company says it is continuing R&D across heart valve diseases and other structural heart disease products to build a comprehensive platform. Financially, 捍宇医疗 has just raised nearly ¥500 million in a D+ round, and investors view the financing as a signal of strong capital support. Management is pursuing a Sci‑Tech Board (科创板) listing and is being counseled by China International Capital Corporation under a formal guidance agreement. Hanyu Medical is a Chinese startup focused on heart valve interventional medical devices. The company is developing a mitral valve repair product that could be China’s first domestically developed device of its kind. Hanyu completed a Series D financing of 500 million yuan (about $72 million). The funds are earmarked to promote premarket clinical trials for its mitral valve repair device. The raise is intended to advance the product through regulatory and clinical milestones toward commercialization in China. Hanyu Medical is a cardiac valve interventional medical device company whose core product is ValveClamp, a minimally invasive mitral‑valve clip for treating mitral regurgitation. ValveClamp holds fully independent domestic patents and has filed an international PCT patent. In July 2018 the company performed the world’s first transapical mitral‑clip procedure at Shanghai Zhongshan Hospital and completed its final exploratory clinical trial by year‑end; multi‑center, large‑sample clinical trials were planned to begin the following year. ValveClamp is positioned to become China’s first and the world’s second widely marketed device for mitral regurgitation and was expected to be launched in 2020. With the new financing, the company plans to accelerate ValveClamp’s commercialization and to strengthen R&D on new products.

Total raised

$163M

Funding rounds

3

Latest round

Series D

Latest activity

Mar 2021